• 1
    O’Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998;34:15008.
  • 2
    Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochim Biophys Acta 1998;1400:10719.
  • 3
    Wilkinson K. Irinotecan Hydrochloride. Clin J Oncol Nurs 2001;5:17981.
  • 4
    Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002;13:84151.
  • 5
    Oneschuk D, Younus J. Natural health products and cancer chemotherapy and radiation therapy. Oncol Rev 2008;1:23342.
  • 6
    Ng TB, Liu F, Wang ZT. Antioxidative activity of natural products from plants. Life Sci 2000;66:70923.
  • 7
    Rice-Evans C. Flavonoid antioxidants. Curr Med Chem 2001;8:797807.
  • 8
    Galati G, Sabzevari O, Wilson JX, O`Brien PJ. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 2002;177:91104.
  • 9
    Meeran SM, Katiyar SK. Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 2008;13:2191202.
  • 10
    Ren W, Qiao Z, Wang H, Zhu L, Zhang L. Flavonoids: promising anticancer agents. Med Res Rev 2003;23:51934.
  • 11
    Khantamat O, Wittaya Chaiwangyen MS, Porn-ngarm Limtrakul MS. Screening of flavonoids for their potential Inhibitory effect on p-glycoprotein activity in human cervical carcinoma Kb cells. Chiang Mai Med Bull 2004;43:4556.
  • 12
    Yamashita Y, Kawada S, Fujii N, Nakano H. Induction of mammalian DNA Topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin. Cancer Res 1990;50:58414.
  • 13
    Webb MR, Ebeler SE. Comparative analysis of Topoisomerase IB inhibition and DNA intercalation by flavonoids and similar compounds: structural determinates of activity. Biochem J 2004;384:52741.
  • 14
    López-Lázaro M, Martín-Cordero C, Toro MV, Ayuso MJ. Flavonoids as DNA Topoisomerase I Poisons. J Enzyme Inhib Med Chem 2006;233:25564.
  • 15
    Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 1995;58:21725.
  • 16
    Orsolic N, Kosalec I, Basic I. Synergystic antitumor effect of polyphenolic components of water soluble derivative of propolis against Ehrlich ascites tumour. Biol Pharm Bull 2005;28:694700.
  • 17
    Benkovic V, Horvat Knezevic A, Brozovic G, Knezevic F, Dikic D, Bevanda M et al. Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on Ehrlich ascites tumor in mice. Biomed Pharmacother 2007;61:2927.
  • 18
    Oršolić N, Benković V, Lisičić D, Dikić D, Erhardt J, Horvat Knežević A. Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan. Med Oncol 2009;27:134658.
  • 19
    Cao S, Durrani FA, Rustum YM. Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer 2005;4:33643.
  • 20
    Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC. Human tumor xenograft models in NCI drug development. In: Teicher B (ed.). Anticancer Development Guide: Preclinical Screening, Clinical Trials and Approval. Humana Press Inc., Totowa, USA, 1997;10125.
  • 21
    Doeing DC, Borowicz J, Crockett ET. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol 2003;3:3.
  • 22
    Bergman RA, Afifi AK, Heidger PM. Histology. Saunders Publishing, Philadelphia, PA, 1995.
  • 23
    Fecchio D, Sirois P, Russo M, Jancar S. Studies on inflammatory response induced by Ehrlich tumor in mice peritoneal cavity. Inflammation 1990;14:12532.
  • 24
    Singh NP, McCoy MT, Tice RR, Schneider LL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;75:18491.
  • 25
    Benković V, Knežević A, Đikić D, Lisičić D, Oršolić N, Bašić I et al. Radioprotective effects of quercetin and ethanolic extract of propolis in gamma-irradiated mice. Arh Hig Rada Toksikol 2009;60:12938.
  • 26
    Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT et al. The antitumor activities of flavonoids. In Vivo 2005;19:895909.
  • 27
    Fresco P, Borges F, Diniz C, Marques MP. New insights on the anticancer properties of dietary polyphenols. Med Res Rev 2006;26:74766.
  • 28
    Liu HL, Jiang WB, Xie MX. Flavonoids: recent advances as anticancer drugs. Recent Pat Anticancer Drug Discov 2010;5:15264.
  • 29
    Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001;74:41825.
  • 30
    Orsolić N, Knezević AH, Sver L, Terzić S, Basić I. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. J Ethnopharmacol 2004;94:30715.
  • 31
    Kopjar N, Zeljezić D, Vrdoljak AL, Radić B, Ramić S, Milić M et al. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Basic Clin Pharmacol Toxicol 2007;100:40313.
  • 32
    Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 2008;11:73340.
  • 33
    González-Gallego J, García-Mediavilla MV, Sánchez-Campos S, Tuñón MJ. Fruit polyphenols, immunity and inflammation. Br J Nutr 2010;104:S1527.
  • 34
    Cotelle N. Role of flavonoids in oxidative stress. Curr Top Med Chem 2001;1:56990.
  • 35
    Lee JC, Kim J, Park JK, Chung GH, Jang YS. The antioxidant, rather than prooxidant, activities of quercetin on normal cells: quercetin protects mouse thymocytes from glucose oxidase-mediated apoptosis. Exp Cell Res 2003;291:38697.
  • 36
    Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2:10323.
  • 37
    Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 2006;29:20930.